MedTrace Logo

A Phase I Study of GZR18 Injection in Healthy Subjects

NCT06548997 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2024-08-14

No results posted yet for this study

Summary

This trial is conducted in China. The aim of the trial is to evaluate the safety and tolerability of GZR18 injection in healthy subjects following single dose and once-weekly dose for 2 consecutive weeks until reaching the target dose.

Conditions

Interventions

DRUG

GZR18

5 μg/kg-maximum tolerated dose (MTD), single dose or two doses

OTHER

Placebo

administered the same volume as GZR18

Sponsors & Collaborators

  • Gan and Lee Pharmaceuticals, USA

    lead INDUSTRY

Principal Investigators

  • Liyuan Zhao, Ph.D · Gan & Lee Pharmaceuticals.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-02
Primary Completion
2022-10-20
Completion
2022-10-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06548997 on ClinicalTrials.gov